Mice Model Market - Analysis & Global Forecast to 2020

Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.

Ongoing innovations in mice models, personalized medicine fuelling the demand for personalized humanized mice models, continuous support in the form of investments and grants, and increase in R&D activities of pharmaceutical industries are some of the factors that are expected to drive the growth of the global mice model market in the coming years.
Market players are continuously focusing on innovations in mice models for research on various human diseases. Growing innovations and advances in mice models are providing increased options to researchers to conduct research activities in particular diseases, which is a major factor driving market growth.
On the other hand, factors like advancements in genetic techniques for the development of genetically modified rats have led to the increased usage of rat models, thereby restraining the mice model market to some extent. In addition, advances in zebrafish model development, increased benefits from cryopreservation, regulations & laws for the ethical use of animals, and alternative methods to animal testing are some factors expected to restrain the growth of the market. Moreover, the continuous need for improved mice models is posing as a major challenge for the global mice model market.
In 2015, the inbred mice are estimated to account for the largest share of the global mice model market, by type while genetically engineered mice models are expected to be the fastest-growing market segment, owing to high investments in the development of new and innovative knockout models that also increases the application areas for the models.

In 2015, North America is expected to account for the largest share of the global mice model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America’s large share is attributed to the revised funding plans by NIH to enhance the reproducibility of results, rising demands for monoclonal antibody production, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The major players in the market are focusing on various strategies (agreements, partnerships, joint ventures, collaborations, geographic expansion, new product launches, funds/grants, licensing, patents, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

‧ Market Penetration: Comprehensive information on the models and services offered by top players in the mice model market. The report analyzes the mice model market, by type, technology, disease, service, and mice care products.
‧ Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the mice model market
‧ Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for mice models & services across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the mice model market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the mice model market

TABLE OF CONTENTS

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH METHODOLOGY STEPS 25
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 26
2.2.1 SECONDARY RESEARCH 26
2.2.1.1 Key data from secondary sources 26
2.2.2 PRIMARY RESEARCH 27
2.2.2.1 Key industry insights 28
2.2.2.2 Key data from primary sources 29
2.2.2.3 Key insights from primary sources 30
2.3 MARKET SIZE ESTIMATION METHODOLOGY 30
2.4 MARKET FORECAST METHODOLOGY 32
2.5 MARKET DATA VALIDATION AND TRIANGULATION 33
2.6 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
3.1 INTRODUCTION 34
3.2 CURRENT SCENARIO 34
3.3 FUTURE OUTLOOK 36
3.4 CONCLUSION 38
4 PREMIUM INSIGHTS 39
4.1 GLOBAL MICE MODEL MARKET 39
4.2 GEOGRAPHIC ANALYSIS: MICE CARE PRODUCTS MARKET, BY TYPE 40
4.3 MICE MODEL MARKET, BY TECHNOLOGY (2015 VS. 2020) 42
?
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 44
5.2 MARKET SEGMENTATION 45
5.3 MARKET DYNAMICS 46
5.3.1 DRIVERS 46
5.3.1.1 Ongoing innovations in mice models 46
5.3.1.1.1 Mice models for immune diseases 46
5.3.1.1.2 Mice models for cancer 47
5.3.1.1.3 Mice models for rare diseases 47
5.3.1.2 Personalized medicine to fuel the demand for personalized humanized mice models 47
5.3.1.3 Continuous support in the form of grants and investments 48
5.3.1.4 Increase in R&D activities of pharmaceutical industries 49
5.3.1.5 Increasing focus of associations on the development of embryonic stem (ES) cells as well as knockout and mutant mice 49
5.3.1.5.1 International Mouse Phenotyping Consortium (IMPC) 49
5.3.1.5.2 International Knockout Mouse Consortium (IKMC) 49
5.3.2 RESTRAINTS 50
5.3.2.1 Increased usage of rat models 50
5.3.2.2 Advances in zebrafish model development 51
5.3.2.3 Increased benefits from cryopreservation 51
5.3.2.4 Regulations and laws for ethical use of animals in research 51
5.3.2.4.1 The Animal Welfare Act (AWA) 52
5.3.2.4.2 Public Health Service Policy (PHS)on Humane Care and Use of Laboratory Animals 52
5.3.2.5 Alternative methods to animal testing 52
5.3.3 OPPORTUNITIES 53
5.3.3.1 Rising demand of humanized mice models 53
5.3.3.2 Increase in monoclonal antibody production 53
5.3.4 CHALLENGE 54
5.3.4.1 Need for improved mice models 54
6 MICE MODEL MARKET, BY TYPE 55
6.1 INTRODUCTION 56
6.2 INBRED MICE 57
6.3 OUTBRED MICE 59
6.4 GENETICALLY ENGINEERED (KNOCKOUT & KNOCKIN) MICE 60
6.5 HYBRID/CONGENIC MICE 62
6.6 CONDITIONED/SURGICALLY MODIFIED MICE 63
6.7 SPONTANEOUS MUTANT MICE 64
?
7 MICE MODEL MARKET, BY TECHNOLOGY 65
7.1 INTRODUCTION 66
7.2 MICROINJECTION 68
7.3 EMBRYONIC STEM CELL INJECTION 69
7.4 NUCLEAR TRANSFERASE 70
7.5 OTHER TECHNOLOGIES 71
7.5.1 GENETICALLY MODIFIED SPERM-MEDIATED GENE TRANSFER 71
7.5.2 VIRUS/VECTOR-MEDIATED GENE TRANSFER 71
7.5.3 LIPOSOME-MEDIATED DNA AND ELECTROPORATION OF DNA 71
7.5.4 BIOLISTICS 71
7.5.5 CRISPR/CAS9, TALENS, AND ZFNS 72
8 MICE MODEL MARKET, BY SERVICE 74
8.1 INTRODUCTION 75
8.2 BREEDING SERVICES 77
8.3 CRYOPRESERVATION SERVICES 78
8.4 QUARANTINE SERVICES 79
8.5 REDERIVATION SERVICES 80
8.6 MODEL IN-LICENSING SERVICES 81
8.7 GENETIC TESTING SERVICES 82
8.8 OTHER SERVICES 83
9 MICE MODEL MARKET, BY DISEASE 85
9.1 INTRODUCTION 86
9.2 ONCOLOGY MICE MODELS 88
9.2.1 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES 89
9.2.2 AGREEMENTS/COLLABORATIONS TO STRENGTHEN CANCER RESEARCH 89
9.2.3 INTRODUCTION OF NEW MICE MODELS FOR SPECIFIC CANCERS 89
9.2.4 EXPANSIONS TO SUPPORT CANCER RESEARCH FACILITIES 90
9.3 MICE MODELS FOR IMMUNOLOGY AND INFLAMMATION STUDIES 91
9.4 MICE MODELS FOR DIABETES STUDIES 93
9.5 MICE MODELS FOR CARDIOVASCULAR STUDIES 94
9.6 MICE MODELS FOR CENTRAL NERVOUS SYSTEM (CNS) STUDIES 95
9.7 MICE MODELS FOR METABOLISM AND REGULATION STUDIES 97
9.8 MICE MODELS FOR OTHER DISEASE STUDIES 98
?
10 MICE CARE PRODUCTS MARKET, BY TYPE 99
10.1 INTRODUCTION 100
10.2 CAGES 102
10.3 FEED 103
10.4 BEDDING 104
10.5 OTHERS 105
11 MICE MODEL MARKET, BY REGION 106
11.1 INTRODUCTION 107
11.2 NORTH AMERICA 109
11.2.1 U.S. 113
11.2.1.1 Revised funding plans by the NIH to enhance reproducibility of results 113
11.2.1.2 Growing biomedical research in the U.S. 113
11.2.1.3 Monoclonal antibody production to augment the use of mice models 115
11.2.1.4 Continued and responsible use of animals ensured by Animal Care Organizations 115
11.2.1.5 Development of biosimilars boosting the demand for preclinical services 116
11.2.1.6 Preclinical activities by CROs and pharmaceutical R&D 117
11.2.1.7 Partnerships between CROs and pharmaceutical companies 117
11.2.2 CANADA 120
11.2.2.1 Growing stem cell research activities in Canada 120
11.3 EUROPE 123
11.3.1 GERMANY 127
11.3.1.1 Launch of Pro-Test Deutschland 127
11.3.1.2 Flourishing biotechnology industry 127
11.3.2 U.K. 130
11.3.2.1 Investors demand strong statistics for animal studies in the U.K. 130
11.3.2.2 Increase in cell therapy preclinical research 130
11.3.3 FRANCE 133
11.3.3.1 Funding for rare disease projects in France 133
11.3.4 REST OF EUROPE (ROE) 135
11.3.4.1 Improving biomedical industry in Russia 135
11.3.4.2 Growth in biosimilars market calls for increased preclinical activities 136
11.3.4.3 Focus on rare disease research projects 137
11.3.4.4 Events conducted by animal care associations to promote the ethical use of mice 137
11.3.4.5 Increase in tailored mice models for diseases like cancer 138
11.4 ASIA-PACIFIC 141
11.4.1 CHINA 145
11.4.1.1 International alliances for R&D activities in China 145
11.4.1.2 Growing foray of pharmaceutical and mice model suppliers in China 145
11.4.1.3 Increasing investments from government and private sectors in China’s life sciences sector 147
11.4.1.4 Initiatives to reduce longer approval times 148
11.4.1.5 Mandatory animal testing for all pharmaceutical drugs and cosmetics in China 149
11.4.1.6 Intellectual property (IP) breaches, a challenge for the Chinese market 149
11.4.2 JAPAN 152
11.4.2.1 Growth in biomedical and medical research in Japan 152
11.4.2.2 Research into regenerative medicines 153
11.4.3 INDIA 155
11.4.3.1 Growing presence of global players 155
11.4.3.2 Development of bioclusters to boost India’s biotechnology industry 155
11.4.3.3 R&D activities by Indian pharmaceutical companies to boost preclinical research 156
11.4.3.4 Likely shift of outsourcing preclinical activities from India towards European nations 157
11.4.3.5 Limited infrastructural facilities in India, a major hindrance to the mice model market 157
11.4.3.6 Weak intellectual property environment in India 158
11.4.4 REST OF ASIA-PACIFIC (ROAPAC) 160
11.4.4.1 Influx of international players 160
11.4.4.2 Ongoing biomedical research activities in Australia to strengthen the market 162
11.4.4.3 Growth in translational and biomedical research in Singapore 162
11.4.4.4 Increase in animal research in Malaysia 163
11.4.4.5 Rising pharmaceutical and biotechnology R&D activities in Korea 164
11.5 REST OF WORLD (ROW) 167
11.5.1.1 Pharmaceutical, biotechnology, and research industries in Brazil to bolster the market 168
11.5.1.2 Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE 168
12 COMPETITIVE LANDSCAPE 172
12.1 OVERVIEW 172
12.2 MICE MODEL MARKET: MARKET SHARE ANALYSIS (2014) 173
12.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 174
12.2.2 THE JACKSON LABORATORY 175
12.2.3 TACONIC BIOSCIENCES, INC. 176
12.2.4 HARLAN LABORATORIES, INC. (ENVIGO) 177
12.3 COMPETITIVE SITUATION AND TRENDS 179
12.3.1 COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES PARTNERSHIPS, AND JOINT VENTURES 180
12.3.2 GRANTS & FUNDS 181
12.3.3 LICENSING 182
12.3.4 NEW PRODUCT LAUNCHES 183
12.3.5 EXPANSIONS 185
12.3.6 PATENTS 186
12.3.7 ACQUISITIONS 187
12.3.8 OTHERS 188
13 COMPANY PROFILES 190
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 INTRODUCTION 190
13.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 191
13.3 THE JACKSON LABORATORY 196
13.4 TACONIC BIOSCIENCES, INC. 202
13.5 ENVIGO 208
13.6 COVANCE, INC. 213
13.7 JANVIER LABS 216
13.8 HARBOUR ANTIBODIES BV 218
13.9 TRANSGENIC, INC. 219
13.10 GENOWAY SA 223
13.11 SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC) 226
13.12 INGENIOUS TARGETING LABORATORY 229
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
14 APPENDIX 231
14.1 DISCUSSION GUIDE 231
14.2 COMPANY DEVELOPMENTS (2012-2015) 237
14.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 237
14.2.2 THE JACKSON LABORATORY (JAX) 237
14.2.3 TACONIC BIOSCIENCES INC. 239
14.2.4 ENVIGO 241
14.2.5 COVANCE, INC. 242
14.2.6 TRANSGENIC, INC. 243
14.2.7 GENOWAY SA 245
14.2.8 SAGE LABS, INC. 245
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 247
14.4 AVAILABLE CUSTOMIZATIONS 247
14.5 RELATED REPORTS 248